Anti-nectin-4 antibody exatecan conjugate
Monoclonal antibodies with enhanced tumor specificity for Nectin-4, conjugated with exatecan, address the limitations of current treatments by providing improved cancer therapy with reduced side effects and enhanced efficacy.
Patent Information
- Application Number
- JP2023561116
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-11-19
- Filing Date
- 2022-03-31
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2042-03-31
AI Technical Summary
Current cancer treatments targeting Nectin-4, such as enfortumab vedotin, face challenges in specificity and efficacy due to non-tumor cell binding, leading to increased side effects and reduced therapeutic index.
Development of monoclonal antibodies, particularly mAb 15A7.5, with enhanced affinity for tumor-expressed Nectin-4 and reduced binding to normal keratinocytes, conjugated with topoisomerase I inhibitors like exatecan, forming antibody-drug conjugates that selectively target and treat Nectin-4-positive cancers.
The antibody-drug conjugates demonstrate improved anti-cancer activity with reduced skin toxicity and higher antitumor selectivity, achieving long-lasting tumor regression in xenograft models.
Smart Images

Figure 0007579991000002 
Figure 0007579991000003 
Figure 0007579991000004
Abstract
Description
[Technical field]
[0001] The present invention relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor, in particular exatecan or deruxtecan. [Background technology]
[0002] 2. Background of the Invention Nectins are adhesion molecules that help organize epithelial and endothelial junctions and serve as receptors for the entry of herpes simplex, measles and polioviruses.
[0003] They belong to the immunoglobulin superfamily and are homologues of the poliovirus receptor (PVR / CD155), and therefore have also been called poliovirus receptor-binding proteins (PRRs). To date, five members have been described: PVR / CD155, nectin-1 / PRR1 / CD111, nectin-2 / PRR2 / CD112, nectin-3 / PRR3 and nectin-4 / PRR4. Their extracellular domains are composed of three immunoglobulin-like (Ig)-type V, C, and C domains that share between 30% and 55% identity in their amino acid sequences.
[0004] Expression of nectin / PRR molecules is generally widespread in tissues including hematopoietic, neuronal, endothelial and epithelial cells, with the exception of nectin-3 and -4, which show a more restricted expression profile.
[0005] Nectin-4 is a particularly interesting target. It is expressed during fetal development, but its expression is reduced and highly restricted in adult tissues compared to that of other members of the nectin family. Nectin-4 is a tumor-associated antigen in 83% of bladder cancers, 78% of breast cancers (mainly triple negative and ERBB2+), 71% of pancreatic cancers, 55% of lung cancers, 57% of ovarian cancers, 59% of head and neck cancers, and 55% of esophageal cancers.
[0006] Expression of Nectin-4 in these pathologies is associated with poor prognosis, possibly as a result of its ability to confer a higher capacity for migration, proliferation and formation of metastases to tumor cells in vitro. In normal tissues, Nectin-4 is only detected in the skin, salivary glands, bladder and esophagus. The recent approval by health authorities of Enfortumab Vedotin for the second-line treatment of advanced urothelial carcinoma has completed the validation of Nectin-4 as a target for the treatment of cancer. Summary of the Invention
[0007] A first aspect of the present invention is an antibody-drug conjugate comprising a monoclonal antibody or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor, in particular exatecan or deruxtecan.
[0008] A further aspect of the invention is a pharmaceutical composition comprising an active agent which is an antibody-drug conjugate comprising a monoclonal antibody or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor, in particular exatecan, and a pharmaceutically acceptable carrier and / or excipient.
[0009] A further aspect of the present invention is the use of an antibody-drug conjugate or a pharmaceutical composition as described above in medicine, in particular in human medicine.
[0010] A further aspect of the present invention is the use of the above-mentioned antibody-drug conjugate or pharmaceutical composition in a method for the prevention and / or treatment of Nectin-4 associated disorders, in particular for the prevention and / or treatment of Nectin-4 positive cancers.
[0011] A further aspect of the invention is the use of an antibody-drug conjugate or a pharmaceutical composition as described above in a method for the prevention and / or treatment of cancer, in particular for the prevention and / or treatment of a cancer selected from bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.
[0012] A further aspect of the present invention is a method for preventing and / or treating Nectin-4 associated disorders, in particular for preventing and / or treating Nectin-4 positive cancers, comprising administering to a subject in need thereof a therapeutically effective amount of the above-mentioned antibody-drug conjugate or pharmaceutical composition.
[0013] A further aspect of the present invention is a method for the prevention and / or treatment of cancer, in particular for the prevention and / or treatment of a cancer selected from bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody-drug conjugate or pharmaceutical composition as described above. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Detailed Description of the Invention The present inventors have found that conjugates of anti-nectin-4 antibodies with topoisomerase-I inhibitors, such as exatecan, demonstrate improved anti-cancer activity compared to the commercially available antibody enfortumab vedotin, which is a conjugate of anti-nectin-4 antibodies and monomethyl auristatin E (MMAE). Thus, the anti-nectin-4 antibody conjugates of the present invention allow for improved treatment of nectin-4-associated disorders, such as nectin-4-positive cancers.
[0015] In a particular embodiment, the antibody-drug conjugate of the present invention comprises a novel anti-nectin-4 antibody that specifically binds with higher affinity to tumor-expressed nectin-4 compared to nectin-4 expressed by human keratinocytes, e.g., in vitro differentiated nectin-4-expressing keratinocytes. Preferred examples are monoclonal antibodies (mAbs) 15A7.5, 9A2.7, 3A1.4 and / or 8F06.
[0016] A particularly preferred example is the monoclonal antibody (mAb) 15A7.5 or an antibody derived therefrom. In vitro, this selectivity provides mAb 15A7.5 with lower binding affinity, internalization and / or cytotoxic activity against keratinocytes compared to tumor cells and with reference to the activity of HA22 mAb (enfortumab) in the same assay.
[0017] In particular, the conjugate of the present invention comprises a humanized antibody derived from the monoclonal anti-Nectin-4 antibody 15A7.5 mAb.
[0018] In vivo, this low binding capacity to keratinocytes confers a longer half-life to mAb 15A7.5 due to a lower absorption rate in the skin.
[0019] In a xenograft mouse model, treatment of established tumors with a single intravenous dose of 4 mg / kg of the mAb conjugated to exatecan led to rapid and durable regression.
[0020] More specifically, the inventors demonstrate that in such a configuration, the antibody-exatecan conjugate is more efficient than a surrogate of enfortumab vedotin, i.e., an enfortumab vedotin product manufactured using non-GMP methods by a third party that is indistinguishable from commercially available enfortumab vedotin.
[0021] antibody The antibody of the conjugate of the invention is a monoclonal antibody (mAb) or monoclonal antibody fragment characterized by a particular amino acid sequence. Unless otherwise indicated, the term "monoclonal" refers to an antibody or antibody fragment of a single species, i.e., of a single amino acid composition.
[0022] The antibodies provided herein preferably exhibit specific binding to Nectin-4 and do not exhibit any substantial reactivity or cross-reactivity to other proteins of the human Nectin family, in particular Nectin-1 and / or rodent Nectin-4, such as Nectin-4 from rat and / or mouse.
[0023] An antigen-binding site of an antibody of the invention comprises an antibody heavy chain variable domain / region (VH) and / or an antibody light chain variable domain / region (VL), or a VH / VL pair.
[0024] The term "antigen-binding site" refers to the region(s) of an antibody molecule derived from an antibody to which a ligand (e.g., an antigen, i.e., Nectin-4, or an antigenic fragment thereof) actually binds.
[0025] Variable domains / regions refer to each of the light and heavy chain pairs that are directly involved in binding the antibody to the antigen. The variable domain of the heavy chain is abbreviated as "VH" and the variable domain of the light chain is abbreviated as "VL".
[0026] The antigen-binding site of the antibody according to the invention may contain six complementarity determining regions (CDRs) that contribute to different extents to the affinity of the binding site for the antigen. There are three heavy chain variable domain CDRs (CDR-H1, CDR-H2 and CDR-H3) and three light chain variable domain CDRs (CDR-L1, CDR-L2 and CDR-L3). Also included within the scope of the invention are functional antigen-binding sites that are composed of fewer CDRs (i.e., the binding specificity is determined by three, four or five CDRs). For example, less than the complete set of six CDRs may be sufficient for binding. In some cases, a VH domain or a VL domain will be sufficient.
[0027] According to the present invention, the VH region or its CDRs alone may constitute a complete antigen-binding site.In certain embodiments, the antibody comprises only the VH region or its CDRs as defined herein.In other embodiments, the antibody comprises the VH region or its CDRs as defined herein together with the VL region or its CDRs, in particular the VL region or its CDRs as defined herein.
[0028] The position of the CDRs within the VH or VL regions may be defined according to Kabat, et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991) or the IMGT numbering system, both of which are known to those skilled in the art. The IMGT numbering has been defined to compare variable domains, whatever the antigen receptor, chain type, or species (Lefranc M.-P., "Unique database numbering system for immunogenetic analysis" Immunology Today, 18, 509 (1997); Lefranc M.-P., "The IMGT unique numbering for Immunoglobulins, T cell receptors and Ig-like domains" The Immunologist, 7, 132-136 (1999)). Unless otherwise specified, the Kabat system is used herein.
[0029] The terms "binding" and "specific binding" as used herein refer to the binding of the antibody of the present invention or its fragment to the epitope of Nectin-4 antigen. The measure of the binding strength of the antibody is called affinity. Methods for determining such binding and / or affinity using in vitro assays are known to those skilled in the art. According to the present invention, detection by flow cytometry, immunohistochemistry and / or fluorescence are described herein and are particularly preferred.
[0030] The affinity of binding of an antibody to an antigen is measured using the terms Ka (rate constant for the association of the antibody from the antibody / antigen complex), KD (dissociation constant), and K dis It is defined by (kD / ka).
[0031] In certain embodiments, the antibody of the conjugate of the invention may be a chimeric antibody, a multispecific antibody, in particular a bispecific antibody, a human antibody, a humanized antibody, or an antigen-binding fragment thereof.
[0032] According to the present invention, a "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular origin or species, while the remainder of the heavy and / or light chain is derived from a different origin or species.
[0033] A "multispecific antibody" binds to two or more different epitopes. The epitopes can be on the same or different antigens. A preferred example of a multispecific antibody is a "bispecific antibody" that binds to two different epitopes.
[0034] In a preferred embodiment, the antibody of the present invention is a humanized antibody.
[0035] The term "humanized antibody" or "humanized version of an antibody" refers to an antibody in which both the heavy and light chains have been humanized as a result of antibody engineering. A humanized chain is typically a chain in which the amino acid sequence of the V region has been altered so that it is closer in homology to the human germline sequence than the germline sequence of the original species when analyzed as a whole. For example, mouse CDRs can be grafted into the framework region of a human antibody to prepare a "humanized antibody". See, for example, Riechmann, L., et al., Nature 332 (1988) 323-327; and Neuberger, MS, et al., Nature 314 (1985) 268-270. Other forms of humanized antibodies encompassed by the present invention are those in which the constant region has been further modified or altered from that of the original antibody to produce the properties according to the present invention. The assessment of humanization is based on the resulting amino acid sequence, not on the methodology itself.
[0036] Another preferred embodiment relates to a conjugate comprising a human antibody.
[0037] The term "human antibody" as used herein is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the state of the art (van Dijk, MA, and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) that, upon immunization, can produce a full repertoire or a selection of human antibodies without endogenous immunoglobulin production.
[0038] The antibody of the conjugate of the present invention may be of any suitable class. The term "class" refers to the type of constant domain or constant region possessed by its heavy chain. As used herein, "constant domain" or "constant region" refers to the totality of domains of an antibody other than the variable region. The constant region is not directly involved in binding the antigen, but exhibits various effector functions. The antibody may be of any of the five major classes of antibodies, in particular the five major classes of human antibodies: IgA, IgD, IgE, IgG, and IgM, or any subclass (isotype) thereof, such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the various classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. According to the present invention, antibodies or fragments thereof of the classes, in particular the human classes IgG, IgA or IgM, are particularly preferred.
[0039] According to a preferred embodiment, the antibody of the conjugate of the invention is selected from the class IgG, in particular the class of human IgG, such as the subclasses IgG1, IgG2, IgG3 or (of) IgG4, the class IgM, the class IgA or an antigen-binding fragment thereof.
[0040] In a particular embodiment, the antibody comprises a constant domain, in particular a heavy chain constant domain, more particularly a heavy chain constant domain of class IgG, in particular of class human IgG, e.g., subclass IgG1, IgG2, IgG3 or (of) IgG4, class IgM, class IgA, with reduced effector function compared to the wild-type sequence of the same subclass, e.g., with reduced binding to Fc receptors. Examples of heavy chain constant domains with reduced effector function may contain at least one of the mutations D265C, L234A, L235A, P331S, L234Q and L235F of the human IgG, e.g., IgG1 or IgG4 sequence.
[0041] An "antigen-binding fragment" of an antibody refers to a molecule that comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments. The term also encompasses fusion proteins, such as fusion proteins with non-immunoglobulin peptides or polypeptides, and conjugates with non-proteinaceous structures, such as labels or toxins. The terms "antigen-binding fragment of an antibody" and "fragment of an antibody" may be used interchangeably herein.
[0042] An antibody or antigen-binding fragment may be monovalent or multivalent, i.e., it may contain a single antigen-binding site or multiple antigen-binding sites. For example, a Fab fragment has a single antigen-binding site, an antibody of the IgG class or an Fv or scFv fragment has two antigen-binding sites, and an antibody of the IgM class has five antigen-binding sites. The term "antibody" also includes heterospecific antibodies with different antigen-binding sites, such as heterobispecific antibodies, in particular antibodies directed against two different epitopes on an antigen. As used herein, an "epitope" is the region of an antigen to which an antibody binds. The term "epitope" includes any polypeptide determinant that can specifically bind to an antibody.
[0043] Tumor-selective anti-Nectin-4 antibody In certain embodiments, the antibody of the conjugate is a tumor-selective anti-Nectin-4 antibody, such as a monoclonal antibody derived from monoclonal antibodies (mAbs) 15A7.5, 9A2.7, 3A1.4 and / or 8F06, that specifically binds with higher affinity to Nectin-4 expressed by tumors compared to Nectin-4 expressed by human keratinocytes, e.g., in vitro differentiated Nectin-4-expressing keratinocytes. mAb 15A7.5 is particularly preferred.
[0044] For comparison, the binding affinity may be detected by flow cytometry, immunohistochemistry and / or fluorescence. Such specific binding allows, inter alia, fewer side effects during therapy based on the antibodies of the invention.
[0045] Thus, antibody-drug conjugates comprising antibodies 15A7.5, 9A2.7, 3A1.4 and / or 8F06, particularly humanized variants derived therefrom, represent a new way to improve the therapeutic index of Nectin-4 positive cancer treatment through lower associated skin toxicity and higher anti-tumor selectivity and efficacy.
[0046] The tumor-selective anti-Nectin-4 antibodies and antigen-binding fragments thereof preferably exhibit a dissociation constant KD of at least 40, preferably at least 45, more preferably at least 50 and most preferably at least 55 (nM).
[0047] In addition to lower binding affinity, the tumor-selective antibodies and fragments provided herein also preferably exhibit lower internalization and / or cytotoxic activity towards keratinocytes compared to tumor cells.
[0048] According to particularly preferred embodiments, the tumor-selective antibodies and fragments exhibit lower binding affinity, lower internalization, and lower cytotoxic activity towards keratinocytes compared to tumor cells.
[0049] Of course, specific binding to tumor-expressed Nectin-4 is preferred.
[0050] According to a further aspect, the present invention also relates to an antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof, characterized in that it binds with higher affinity to tumor-expressed Nectin-4 compared to human keratinocyte-expressed Nectin-4. For comparison, the binding affinity may be detected by flow cytometry, immunohistochemistry and / or fluorescence.
[0051] In certain embodiments, the tumor-selective monoclonal anti-Nectin-4 antibody or antigen-binding fragment thereof comprises: (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 comprises an amino acid sequence according to SEQ ID NO: 1, 7, 88, 96, or 104, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 is an amino acid sequence according to SEQ ID NO: 2, 8, 89, 97 or 105, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 is an amino acid sequence according to SEQ ID NO: 3, 9, 90, 98 or 106, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 4, 10, 92, 100 or 108, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 5, 11, 93, 101 or 109, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 6, 12, 94, 102 or 110, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, Includes.
[0052] SEQ ID NOs: 1-6 define the six CDR sequences of the parent antibody 15A7.5 of the invention according to the IMGT numbering system. SEQ ID NOs: 7-12 define the six CDR sequences of the parent antibody of the invention according to Kabat.
[0053] Specific amino acid sequences for the SEQ ID NOs used herein are provided in the accompanying sequence listing.
[0054] SEQ ID NOs:88-95 characterize mAb 9A2.7.
[0055] SEQ ID NOs: 96-103 characterize mAb 3A1.4.
[0056] SEQ ID NOs: 104 to 111 characterize mAb 8F06.
[0057] According to the present invention, substitution or insertion of at least one amino acid, for example one or two amino acids, in these CDR sequences is possible.In certain embodiments, conservative amino acid substitution, i.e. substitution of an amino acid with another amino acid having similar biochemical properties, for example substitution of an aliphatic amino acid, for example Gly, Ala, Val, Leu or Ile, for another aliphatic amino acid, substitution of a basic amino acid, for example His, Lys or Arg, substitution of an acidic amino acid or its amide, for example Asp, Glu, Asn or Gln, substitution of an aromatic amino acid, for example Phe, Tyr or Trp, or substitution of a hydroxyl or sulfur-containing amino acid, for example Ser, Thr, Met or Cys, for another hydroxyl or sulfur-containing amino acid.In further specific embodiments, at least one amino acid, for example one or two histidine residues, is inserted into one or more CDR sequences of heavy or light chain, for example CDR1, CDR2 or CDR3. This could result in preferential binding at low pH, eg, between pH 5.5 and 6.5, versus neutral pH, eg, pH 7.0 to 7.5.
[0058] According to a further preferred embodiment, the antibody or antigen-binding fragment thereof is numbered according to the IMGT numbering system: (i) a VH region comprising CDR-H1 of SEQ ID NO: 1, CDR-H2 of SEQ ID NO: 2, and CDR-H3 of SEQ ID NO: 3; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6 Includes.
[0059] In another preferred embodiment, the antibody or antigen-binding fragment thereof is (i) a VH region comprising CDR-H1 of SEQ ID NO: 7, CDR-H2 of SEQ ID NO: 8, and CDR-H3 of SEQ ID NO: 9; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 10, CDR-L2 of SEQ ID NO: 11, and CDR-L3 of SEQ ID NO: 12 Includes.
[0060] In another preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (i) a VH region comprising a CDR-H1 of SEQ ID NO: 88, a CDR- of SEQ ID NO: 89, and a CDR-H3 of SEQ ID NO: 90; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 92, CDR-L2 of SEQ ID NO: 93 and CDR-L3 of SEQ ID NO: 94 Includes.
[0061] In another preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (i) a VH region comprising a CDR-H1 of SEQ ID NO: 96, a CDR- of SEQ ID NO: 97, and a CDR-H3 of SEQ ID NO: 98; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 100, CDR-L2 of SEQ ID NO: 101 and CDR-L3 of SEQ ID NO: 102 Includes.
[0062] In another preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (i) a VH region comprising CDR-H1 of SEQ ID NO: 104, CDR-H2 of SEQ ID NO: 105, and CDR-H3 of SEQ ID NO: 106; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 108, CDR-L2 of SEQ ID NO: 109 and CDR-L3 of SEQ ID NO: 110 Includes.
[0063] More specifically, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 13, 91, 99 or 107, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, 95, 103 or 111, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0064] In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0065] In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 91, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 95, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0066] In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 99, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0067] In a preferred embodiment, the antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 107, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 111, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0068] "Percent (%) amino acid sequence identity" with respect to a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a particular peptide or polypeptide sequence that are identical to the amino acid residues in that sequence after aligning the candidate sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be accomplished in a variety of ways that are within the skill of one of ordinary skill in the art, for example, using publicly available computer software such as BLAST.
[0069] In a particular embodiment, the humanized or human antibody of the invention is defined by a combination of at least three, and preferably six, complementarity determining regions (CDRs), i.e. (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 21, 35, 49 or 63, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 22, 36, 50 or 64, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 23, 37, 51 or 65, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 24, 38, 52 or 66, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 25, 39, 53 or 67, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 26, 40, 54 or 68, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, The present invention relates to an antibody or antigen-binding fragment thereof comprising:
[0070] Particular humanized or human antibodies according to the invention include (a)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (b)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (c)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (d)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (e)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (f)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 54; or (g)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (h)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (j) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (k) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (l)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (m)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (n) (i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (o)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (p)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (q)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54 may include.
[0071] Particularly preferred are the humanized antibodies (a), (b), (c), (d), (j), (k), (n) and (q) as defined above.
[0072] In a particular embodiment, the humanized or human antibody of the invention is defined by a combination of at least three, and preferably six, complementarity determining regions (CDRs), i.e. (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 21, 35, 49 or 63, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 22, 36, 50 or 64, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 23, 37, 51 or 65, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 24, 38, 52 or 66, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 25, 39, 53 or 67, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 26, 40, 54 or 68, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, The present invention relates to an antibody or antigen-binding fragment thereof comprising:
[0073] Particular humanized or human antibodies according to the invention include (a)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (b)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (c)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (d)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (e)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (f)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (g)(i) a VH region comprising CDR-H1 of SEQ ID NO: 21, CDR-H2 of SEQ ID NO: 22, and CDR-H3 of SEQ ID NO: 23; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (h)(i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (j) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54; or (k) (i) a VH region comprising CDR-H1 of SEQ ID NO: 35, CDR-H2 of SEQ ID NO: 36, and CDR-H3 of SEQ ID NO: 37; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (l)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (m)(i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (n) (i) a VH region comprising CDR-H1 of SEQ ID NO: 49, CDR-H2 of SEQ ID NO: 50, and CDR-H3 of SEQ ID NO: 51; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 66, CDR-L2 of SEQ ID NO: 67, and CDR-L3 of SEQ ID NO: 68; or (o)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 24, CDR-L2 of SEQ ID NO: 25, and CDR-L3 of SEQ ID NO: 26; or (p)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 38, CDR-L2 of SEQ ID NO: 39, and CDR-L3 of SEQ ID NO: 40; or (q)(i) a VH region comprising CDR-H1 of SEQ ID NO: 63, CDR-H2 of SEQ ID NO: 64, and CDR-H3 of SEQ ID NO: 65; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 52, CDR-L2 of SEQ ID NO: 53, and CDR-L3 of SEQ ID NO: 54 may include.
[0074] Particularly preferred are the humanized antibodies (a), (b), (c), (d), (j), (k), (n) and (q) as defined above.
[0075] Of course, humanized or human antibodies according to the invention can also be defined by their VH and / or VL regions.
[0076] Such antibodies are (i) a VH region comprising an amino acid sequence selected from SEQ ID NO: 27, 41, 55, or 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence selected from SEQ ID NOs: 28, 42, 56, 70 or 71, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. may include.
[0077] Particular humanized or human antibodies according to the invention may be defined by their VH and / or VL regions, where such antibodies comprise: (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (b)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (c)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (d)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 71, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (e)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (f)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (g)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 71, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (h)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (j)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (k)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 71, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (l)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (n)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 71, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (o)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (p)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (q)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. Includes.
[0078] Particularly preferred are the humanized antibodies (a), (b), (c), (d), (j), (k), (n) and (q) as defined above.
[0079] Further anti-Nectin-4 antibodies In a further embodiment, the antibody of the conjugate of the invention is the antibody 5A12.2 or an antigen-binding fragment thereof.
[0080] SEQ ID NOs:80-87 characterize mAb 5A12.2.
[0081] In a preferred embodiment, the 5A12.2 antibody or antigen-binding fragment thereof comprises: (i) a VH region comprising CDR-H1 of SEQ ID NO: 80, CDR- of SEQ ID NO: 81, and CDR-H3 of SEQ ID NO: 82; and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 84, CDR-L2 of SEQ ID NO: 85 and CDR-L3 of SEQ ID NO: 86 Includes.
[0082] In another preferred embodiment, the 5A12.2 antibody or antigen-binding fragment thereof comprises: (a) a VH region comprising an amino acid sequence according to SEQ ID NO: 83, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto over the entire length of said sequence; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 87, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto over the entire length of said sequence. may include.
[0083] In a further embodiment, the antibody of the conjugate of the invention is the antibody HA22, which is the antibody of the commercially available antibody-drug conjugate enfortumab vedotin, or an antibody derived from HA22.
[0084] HA22 is a human monoclonal anti-nectin-4 antibody described in WO2012 / 047724, the contents of which are incorporated herein by reference. HA22 antibody or HA22-derived antibody specifically refers to an IgG1 antibody comprising a constant region with reduced effector function as described above, for example, a heavy chain G1m17 or G1m3 haplotype sequence, optionally with TM mutations: P331S, L234Q and L235F, or LALA mutations: L234A and L235A, and a kappa light chain sequence. In particular, the VH sequence of HA22 and its human IgG1 constant region are shown in FIG. 3A of WO2012 / 047724, and the VL sequence of HA22 and its human kappa constant region are shown in FIG. 3B of WO2012 / 047724.
[0085] In certain embodiments, the monoclonal anti-Nectin-4 antibody or antigen-binding fragment thereof derived from HA22 is defined by its CDR sequences: (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 has an amino acid sequence according to SEQ ID NO: 72, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 73, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 74, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 has an amino acid sequence according to SEQ ID NO: 75, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 has an amino acid sequence according to SEQ ID NO: 76, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 has an amino acid sequence according to SEQ ID NO: 77, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, Includes.
[0086] SEQ ID NOs: 72-77 define the six CDR sequences of the parent antibody HA22 according to the IMGT numbering system.
[0087] In certain embodiments, HA22 derived antibodies may be defined by their VH and / or VL regions, where such antibodies are (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 78, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 79, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. Includes.
[0088] In an even more particular embodiment, the HA22 derived antibody is (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 78; and (ii) a VH region comprising an amino acid sequence according to SEQ ID NO: 79 Includes.
[0089] Topoisomerase I Inhibitors The drug of the antibody conjugate of the present invention is a topoisomerase I inhibitor.Topoisomerase I inhibitor is a compound that can form a ternary complex with topoisomerase I and DNA, thereby preventing DNA religation and introducing DNA strand breaks in cell genome.Topoisomerase I inhibitor can be selected from, for example, camptothecin or its analogs indenoisoquinoline and indolocarbazole.
[0090] In certain embodiments, the topoisomerase-I inhibitor is camptothecin or its analogs, i.e., compounds that contain the pentacyclic basic structure of camptothecin and optionally modified substituents that result in the presence of additional rings.Specific examples are camptothecin, topotecan, irinotecan, SN-38, belotecan, exatecan, including their derivatives such as deruxtecan, lurtotecan or atiratecan.
[0091] In certain embodiments, the topoisomerase I inhibitor is exatecan.
[0092] [ka]
[0093] Exatecan is typically used in its NH 2 The antibody is conjugated to the antibody via a group.
[0094] Conjugation The topoisomerase-I inhibitor, particularly exatecan, is covalently conjugated to the antibody or antigen-binding fragment thereof.
[0095] In principle, topoisomerase-I inhibitors, such as exatecan, can be conjugated to any suitable position of monoclonal antibody or its antigen-binding fragment, particularly any position that does not abolish the binding of the antibody to nectin-4.For example, topoisomerase-I inhibitors, such as exatecan, can be conjugated to reactive amino acid residues on antibody, such as amino acid residues with side chains that contain amino, hydroxy or thiol groups, or reactive groups in antibody glycan structures.In certain embodiments, topoisomerase-I inhibitors, such as exatecan, are conjugated to reactive thiol groups in the side chains of accessible cysteine residues on antibody.
[0096] In certain embodiments, the antibody drug conjugate has a drug-antibody / antibody fragment molar ratio (DAR) greater than 1, i.e., more than one drug molecule is attached to the antibody / antibody fragment. Typically, the conjugate has a DAR of about 2:1 to about 16:1, specifically about 4:1 to about 10:1, and more specifically about 6:1 to about 8:1. The DAR can be calculated from statistical distribution according to known methods.
[0097] In certain embodiments, the topoisomerase-I inhibitor is conjugated to the antibody or antigen-binding fragment via a linker.In certain embodiments, the linker is a cleavable linker, i.e., a linker that can be cleaved under physiological conditions, for example, by physiological enzymes.Specific examples of cleavable linkers are peptide-based linkers that can be cleaved by proteases, or glycoside-based linkers that can be cleaved by glycosidases.
[0098] In certain embodiments, the linker is a hydrophilic polysarcosine linker, as described, for example, by Conilh et al. "Exatecan antibody drug conjugates based on a hydrophilic polysarcosine drug-linker platform" (Pharmaceuticals 14 (2021), 247). Further preferred linkers include linkers comprising at least one ethylene glycol unit, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more ethylene glycol units, such as the linker of the antibody-drug conjugate MEDI7247, the mcc-triazole spacer-PEG7-x-Lys-PABC glycol linker from Trodelvy®. Further preferred linkers include oligopeptides, particularly di- to deca-peptides, such as tetrapeptide sequences, such as glycine-glycine-phenylalanine-glycine from Enhertu®. Further preferred linkers include highly polar spacers such as acyl, carbamoyl and / or sulfamide groups attached to at least one ethylene glycol unit, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more ethylene glycol units, e.g., linker technology known as Hydraspace™.
[0099] In certain embodiments, the linker is a hydrophilic polysarcosine linker, e.g., comprising up to 15 sarcosine units and at least one ethylene glycol unit, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more ethylene glycol units, where the linker is subject to cleavage by glycosidases, in particular by glucuronidase.
[0100] In certain embodiments, the linker is a hydrophilic polysarcosine linker, e.g., comprising about 8-12 sarcosine units and at least one ethylene glycol unit, e.g., up to 10 ethylene glycol units, where the linker is subject to cleavage by glycosidases, particularly glucuronidases.
[0101] In certain embodiments, the linker is a hydrophilic polysarcosine linker comprising 10 sarcosine units and 2 ethylene glycol units, where the linker is subject to cleavage by glucuronidase.
[0102] The antibody drug conjugates of the present invention can be prepared by known methods.
[0103] The antibody or antigen-binding fragment thereof may be produced in a suitable host cell comprising a nucleic acid molecule, e.g., a DNA molecule, encoding an antibody VH region, or an antibody VL region, or encoding a complete antibody or antibody fragment, or a vector or vector system, i.e., a plurality of vectors, comprising said nucleic acid molecule(s), preferably operably linked to an expression control sequence, in particular a heterologous expression control sequence. The host cell may be any known host cell for producing antibodies or antibody fragments, e.g., a prokaryotic cell such as an E. coli cell, a yeast cell, an insect cell, or a mammalian cell, e.g., a CHO cell or a hybridoma cell.
[0104] The antibody or its antigen-binding fragment can be reacted with a linker-drug conjugate to obtain an antibody-drug conjugate. The linker-drug conjugate can, for example, comprise a drug molecule having a suitable linker attached thereto, where the linker comprises a reactive group that can react with a desired binding site on the antibody or its antigen-binding fragment. For binding to a cysteine residue, the linker-drug conjugate comprises a thiol-reactive group, for example a maleimide group.
[0105] A further aspect of the present invention is (i) a hydrophilic polysarcosine linker comprising, for example, about 8-12 sarcosine units and at least one ethylene glycol unit, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more ethylene glycol units, wherein the linker is subject to cleavage by glycosidases, in particular cleavage by glucuronidase, and wherein the linker comprises a thiol-reactive group, for example, a maleimide group, capable of reacting with a cysteine residue on an antibody or antigen-binding fragment thereof; and (ii) a topoisomerase I inhibitor, in particular exatecan, covalently attached to the linker The present invention relates to a linker-drug conjugate comprising:
[0106] In certain embodiments, the linker-drug conjugate is (i) a hydrophilic polysarcosine linker comprising 10 sarcosine units and 2 ethylene glycol units, said linker being susceptible to cleavage by glycosidases, in particular by glucuronidase, and said linker comprising a maleimide group capable of reacting with a cysteine residue on an antibody or antigen-binding fragment thereof; and (ii) exatecan covalently attached to the linker Includes.
[0107] The linker-drug conjugate is particularly suitable for binding to the anti-Nectin-4 antibody described herein. However, it should be noted that the linker-drug conjugate is also suitable for binding to any antibody or antigen-binding fragment thereof, such as an antibody or antigen-binding fragment thereof that binds to a tumor antigen.
[0108] Pharmaceutical Compositions A further aspect of the present invention is a pharmaceutical composition comprising an active agent which is an antibody-drug conjugate comprising a monoclonal antibody or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor, in particular exatecan, and a pharmaceutically acceptable carrier and / or excipient.
[0109] Examples of suitable carriers and excipients for formulating antibody drug conjugates include saline and aqueous buffer solutions and are well known in the art.Typically, the pharmaceutical composition is adapted for parenteral administration, for example, subcutaneous, intramuscular, or intravenous injection or infusion.In a further embodiment, the pharmaceutical composition is adapted for local administration, for example, intravesical instillation into the bladder.
[0110] Depending on the stage and severity of the disorder, the pharmaceutical composition may be administered once or several times to a subject in need thereof, particularly a human subject, in a therapeutically effective dose.For example, it may be administered once or several times a day, every other day, twice a week or once a week for a suitable period, for example, at least one week, or at least one month.
[0111] Medical Use According to a further aspect of the invention, the above described antibody-drug conjugate or pharmaceutical composition is for use in medicine, including human and veterinary medicine, in particular in human medicine.
[0112] In a particular embodiment, the above-mentioned antibody-drug conjugate or pharmaceutical composition is used in a method for the prevention and / or treatment of Nectin-4 associated disorders, particularly for the prevention and / or treatment of Nectin-4 positive cancers, more particularly for the prevention and / or treatment of cancers associated with Nectin-4 overexpression.
[0113] The cancer to be prevented and / or treated may be any type of cancer, where the term "cancer" is used herein to refer to a proliferative disease. The cancer to be prevented and / or treated according to the present invention is preferably selected from the group consisting of bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.
[0114] In therapeutic applications, active agents are administered to a subject in need thereof, particularly a human subject, in an effective amount. The dosage will depend on the specific type of agent, e.g., type of antibody or antibody fragment, type of disease, and mode of administration, e.g., local or systemic.
[0115] In the prevention and / or treatment of cancer, the therapeutic dose of an antibody drug conjugate is typically from about 0.3 mg / kg to about 10 mg / kg.
[0116] The antibody drug conjugate may be administered alone or together with a further active agent which may be selected from a chemotherapeutic agent, e.g., antimetabolite, alkylating, intercalating, or antimitotic agent), an inhibitor of a specific kinase, e.g., a tyrosine kinase inhibitor, a serine / threonine kinase inhibitor, or a phosphoinositide kinase inhibitor, an immunotherapeutic compound, e.g., an immune checkpoint inhibitor, a CAR-T cell, a therapeutic vaccine, or an oncolytic virus.
[0117] The invention is further illustrated in more detail by the following tables, figures and examples. [Brief description of the drawings]
[0118] figure [Figure 1]Ch-15A7.5 and Ch-5A12.2 recognize human nectin-4. Detection by flow cytometry. Flow cytometric analysis of MDA-MB231 transfected with an N-terminal Flag-tagged epitope of nectin-4 using a range of doses (0.3 ng / mL to 5 μg / mL) of Ch-15A7 or Ch-5A12.2 antibodies. Parental MDA-MB231 cells are included as a control. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Inlay: staining of parental MDA-MB231 cells with anti-nectin-1, -2 and -3 mAbs (5 μg / mL). Mean fluorescence intensity is represented. [Diagram 2] Ch-15A7.5 recognizes the IgV-like domain of human nectin-4. Detection by ELISA. 96-well plates were coated overnight at 4° C. with 5 μg / mL of nectin-1 extracellular domain Fc fusion recombinant protein (Nec1-VCC), or nectin-4 IgV-like domain Fc fusion recombinant protein (Nec4-V), or nectin-4 extracellular domain Fc fusion recombinant protein (Nec4-VCC), as indicated. Ch15A7.5 recognizes the nectin-4 extracellular domain, more precisely the nectin-4 IgV-like domain, but not the nectin-1 extracellular domain. [Diagram 3] Characterization of the Ch-15A7.5 epitope. Competitive assays were performed by ELISA. 96-well plates were coated with 5 μg / mL of Nectin-4 extracellular domain Fc fusion recombinant protein (Nec4-VCC) overnight at 4 °C. Binding of peroxidase-conjugated Ch-15A7.5 mAb (5 μg / mL) was measured in the presence of increasing concentrations (2.75 ng / mL to 6 μg / mL) of Rituximab, Ch-15A7 mAb, Enfortumab (HA22), Ch-N41 mAb and Ch-14A5 mAb. HA22, Ch-N41 and CH-14A5 recognize the IgV domain of Nectin-4. [Figure 4]Competition of Ch-15A7.5 mAb and Ch-5A12.2 mAb with Nectin-1 for Nectin-4 binding. Competition was assessed by flow cytometry. 50,000 CHO cells transfected with human Nectin-4 cDNA were seeded in 96-well plates. Cells were incubated with increasing concentrations (8 ng / mL to 5 μg / mL) of isotype control, Ch-15A7.5 mAb or Ch-5A12.2 mAb for 45 min. After washing, plates were incubated with 20 μg / mL of Nectin-1 extracellular domain Fc fusion recombinant protein (Nec1-VCC). Nectin-1 binding was revealed after incubation with goat anti-human Fc antibody conjugated to phycoerythrin. [Diagram 5] Cross-reactivity with Nectin-4 from cynomolgus monkeys, rats and mice. Detection by flow cytometry. Flow cytometric analysis of CHO cells transfected with Nectin-4 from cynomolgus monkeys, rats or mice using a range of doses (0.05 ng / mL to 5 μg / mL) of Ch-15A7 (A), Ch-3A1.4 (B), Ch-5A12.2 (C), Ch-9A2.7 (D) or Enfortumab (HA22, B) antibodies. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. The table reports estimated EC50 values determined by GraphPad Prism 9 software using nonlinear curve fitting (4 parameters). The ~ symbol indicates that the reported value is ambiguous due to poor curve fitting. [Figure 6]Differential binding to nectin-4 expressed by tumor cell lines and normal differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell lines (SUM190, filled symbols) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, open symbols) using a range of doses (1.2 ng / mL to 5 μg / mL) of enfortumab (HA22, squares), Ch-15A7.5 (circles), Ch-3A1.4 (triangles) and Ch-9A2.7 (diamonds). Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Nonlinear curve fitting (4 parameters) was performed using GraphPad Prism 9 software. The horizontal bar is placed at 50% of the maximum staining intensity obtained with HA22 antibody on SUM190 cells. [Figure 7] Differential binding to nectin-4 expressed by tumor cell lines and normally differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell line (SUM190, A) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, B) using 5 μg / mL of HA22 (enfortumab), Ch-5A12.2, Ch-15A7.5, and Ch-8F06. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. [Figure 8] Differential binding to nectin-4 expressed by tumor cell lines and human keratinocytes. Detection by immunohistochemistry. Cryopreserved OCT-embedded blocks of a high-expressing nectin-4 tumor cell line (SUM190), a low-expressing nectin-4 tumor cell line (SUM149), human and cynomolgus skin were processed for staining with 15A7.5 mAb (A) and 9A2.7 mAb (B). The reported quick scores for each mAb are shown (A, B). C, Ratio of quick scores SUM190 on human skin. [Figure 9]Differential internalization in tumor cell lines and human keratinocytes. Detection by fluorescence. Enfortumab (HA22), Ch-15A7.5 and isotype control mAb were conjugated to pHAB thiol-reactive dye to reach dye-antibody ratios between 4.58 and 5.55. A range of doses (1.6ng / mL to 5μg / mL) of each of these antibody-dye conjugates were incubated in duplicate with SUM190PT nectin-4 expressing cell line (A) and normal human differentiated (0.1mM CaCl2) keratinocytes (B). Intracellular fluorescence was recorded after 24 hours with a fluorescence microplate reader (ClarioStar). Fluorescence intensity is reported as a function of dye-antibody conjugate concentration. [Figure 10] Differential in vitro cytotoxic activity against tumor cells and normal differentiated human keratinocytes. Cell viability measured by MTT assay. Enfortumab (HA22, diamonds), Ch-15A7.5 (triangles) and Ch-9A2.7 (squares) mAbs were conjugated with α-amanitin to generate antibody-drug conjugates and their cytotoxic activity in a dose range (7.7 pg / mL-15 μg / mL) was comparatively evaluated against SUM190PT nectin-4 expressing cell line (A, D) or normal human differentiated (0.1 mM CaCl2) keratinocytes (B, E). Viability (MTT assay) after a 5-day incubation period is reported. EC50 values were determined by GraphPad Prism 9 software using nonlinear curve fitting (4 parameters). For each condition, the ratio of EC50 of Ch-15A7.5 ADC (C) or Ch-9A2.7 ADC (F) to EC50 of HA22-ADC was calculated and reported. Data shown are representative of three independent donors for two different Nectin-4 expressing tumor cell lines (SUM190PT and MDA-MB468) and human keratinocytes. [Figure 11]Treatment of NSG mice implanted with SUM190 with Ch-15A7.5-MA-PS-βGlu-exatecan ADC induces a durable period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-MA-PS-βGlu-exatecan and Ch-15A7.5-MA-PS-βGlu-exatecan, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE. Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. Ch-15A7.5-MA-PS-βGlu-exatecan (Ch-15A7.5-Ex) and Ch-5A12.2-MA-PS-βGlu-exatecan (Ch-5A12.2-Ex) were evaluated at two doses (4 or 8 mg / kg), ICT-MA-PS-βGlu-exatecan (ICT-Ex) was given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 12] Apparent affinity of humanized variants for tumor cells. Detection by flow cytometry. T47D human tumor cells expressing Nectin-4 were numbered and incubated with a range of doses (169 pg / mL to 30 μg / mL) of Ch-15A7.5 or the indicated humanized variants. Numbers associated with H and L refer to the number of backmutations introduced. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody and analyzed by flow cytometry. Mean fluorescence intensity is reported. GraphPad Prism 9 software used nonlinear curve fitting (4 parameters). [Figure 13]Treatment of NSG mice implanted with SUM190 with HA22-MA-PS-βGlu-E-exatecan ADC induces a durable period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Three different ADCs were tested: isotype controls ICT-MA-PS-βGlu-exatecan and HA22-MA-PS-βGlu-exatecan, as well as the enfortumab vedotin surrogate HA22-MC-vc-PABC-MMAE. Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. HA22MA-PS-βGlu-exatecan (HA22-Ex) was evaluated at two doses (4 or 8 mg / kg), ICT-MA-PS-βGlu-exatecan (ICT-Ex) was given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was monitored twice weekly thereafter with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 14]Treatment of NSG mice implanted with SUM190 with HA22-MA-PS-βGlu-E-exatecan and HA22-MC-GGFG-DX8951 ADCs induces a long-lasting period of tumor regression. NSG mice (n=5 / group) were orthotopically xenografted bilaterally with SUM190PT cells embedded in Matrigel. Five different ADCs were tested: isotype controls, ICT- and HA22 combined with either MA-PS-βGlu-exatecan (ICT-Ex and HA22-Ex) or MC-GGFG-DX8951 (ICT- and HA22-Dxd), and the enfortumab vedotin surrogate, HA22-MC-vc-PABC-MMAE (EV). Treatment of mice (single intravenous injection) began when tumors reached approximately 150 mm3. HA22-Ex and HA22-Dxd were evaluated at two doses (4 or 8 mg / kg), ICT-EX and ICT-Dxd were given at 8 mg / kg, and enfortumab vedotin (EV) surrogate was given at 4 mg / kg. Tumor size (n=10 / group) was subsequently monitored twice weekly with calipers and size was reported using the following formula (L×l×h×Pi / 6). [Figure 15] Differential binding of Ch-15A7.5 and its humanized variants to nectin-4 expressed by tumor cell lines and normally differentiated human keratinocytes. Detection by flow cytometry. Flow cytometric analysis of TNBC cell lines (SUM190, top panel) and normally differentiated (0.1 mM CaCl2) human keratinocytes (NHEK, bottom panel) using a range of doses (8 pM to 33 nM) of Ch-5A12.2, Ch-15A7.5 and its humanized variants 15A7.5-H1L2, -H1L3, -H2L2, -H2L3, -H3L0, -H3L2, -H3L3. Cells were then stained with phycoerythrin-conjugated goat anti-human Fc antibody. Normalized mean fluorescence intensity is shown. Nonlinear curve fitting (4 parameters) was performed using GraphPad Prism 9 software. Note the much lower apparent EC50 of Ch-15A7.5 and its humanized variants against keratinocytes (bottom panel) compared to the EC50 of Ch-5A12.2. [Figure 16] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the parent antibody clone 5A12.2. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 17] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 9A2.7. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 18] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 3A1.4. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 19] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the humanized variants of 8F06. The H-CDR and L-CDR sequences according to the IMTG nomenclature are underlined. [Figure 20] Amino acid sequences of the variable heavy (VH) and variable light (VL) chains of the humanized variant of 15A7.5. The H-CDR and L-CDR sequences according to the IMTG nomenclature are shaded in grey. [Figure 21] Affinity values of humanized 15A7.5 variants. [Figure 22] Amino acid sequences of the variable heavy (VH) and variable light (VK) chains of the parent antibody clone 15A7.5. The sequences of the H-CDR and L-CDR according to the IMTG nomenclature are shaded in grey. [Diagram 23] Amino acid sequences of the variable heavy (VH) and variable light kappa (VK) chains of antibody HA22. The H-CDR and L-CDR sequences according to the IMTG nomenclature are shaded in grey. EXAMPLES
[0119] material and method Cell line: Human breast cancer cell line MDA-MB231 (ATCC, Manassas, VA) was cultured in DMEM supplemented with 10% fetal bovine serum, 50 IU / mL penicillin, 50 μg / mL streptomycin and 2 mM glutamine. Cells were transfected with expression vector p3XFLR4.C1 containing PVRL4 cDNA. Human triple-negative breast cancer cell line SUM190PT (BioIVT, Westbury, NY) was cultured in Ham's F12 medium with 5% fetal bovine serum, 1% non-essential amino acids, 1% Hepes, 1% insulin, 1 μg / mL hydrocortisone, 6.8 ng / mL triiodo-L-tyrosine, 100 IU / mL penicillin, 100 μg / mL streptomycin and 2 mM glutamine. Chinese hamster ovary CHO cell lines were cultured in DMEM supplemented with 10% fetal bovine serum, 100 IU / mL penicillin, 100 μg / mL streptomycin, and 2 mM glutamine. Human breast cancer MDA-MB-468 and T47D cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 IU / mL penicillin, and 100 μg / mL streptomycin.
[0120] ELISA: A sandwich enzyme-linked immunosorbent assay was used to control the specificity of the Ch-15A7.5 antibody and to perform competition assays between the different mAbs. 96-well plates were coated overnight at +4°C with 10 nM of Nectin-4-VCC-Fc, Nectin-1-VCC-Fc (whole extracellular part) or Nectin-4-V-Fc (containing only the IgV domain). After washing and saturation with PBS 1% BSA, cells were incubated with 10 nM of peroxidase-conjugated Ch-15A7.5 mAb for 2 h at 25°C. In the case of competition, binding of 0.5 nM of peroxidase-conjugated Ch-15A7.5 mAb was measured in the presence of variable concentrations (0.018 nM to 40 nM) of "cold" mAb. 100 μL of peroxidase substrate was added (One Step ABST, Pierce) and the OD was read at 405 nm.
[0121] Flow cytometry: Cells or cell lines expressing Nectin-4 (native or transfected) (10,000-50,000) were incubated with a dose range of the indicated antibodies. After washing, cells were then stained with phycoerythrin-conjugated goat anti-human antibody (5 μg / mL, Jackson Immuno Research). After fixation, cells were stained with a viability dye (e780, Invitrogen) prior to flow cytometry acquisition.
[0122] Immunohistochemistry: Frozen samples stored at -80°C were kept on dry ice, placed in plastic cryomolds to allow for maximizing the number of subsequent sections, and embedded in Optimal Cutting Temperature (OCT) medium. Frozen blocks of OCT were mounted on OCT disks and cryosectioning was performed at -20°C on a NX70 cryostat (Thermo Scientific). Frozen sections (7 μm) were mounted on Superfrost Plus slides (VWR). Only the number of slides required for each series of studies were prepared and stored at -80°C until use. The remaining blocks were stored at -80°C until further use. Sections were placed on slides and fixed in acetone at -20°C for 10 min. As part of the Roche DAB kit protocol, endogenous peroxidase was inhibited by immersing the slides in hydrogen peroxide (H 2 O 2) for inhibition. Several dilutions of each mAb were tested to optimize the noise-to-signal ratio, and 0.5 μg / mL of mouse 15A7.5 mAb and 10 μg / mL of mouse 9A2.7 mAb were determined as optimal. To reduce non-specific binding of the secondary antibody to mouse tissues, rabbit anti-mouse IgG (4 μg / mL, Abcam) was added after the primary Ab incubation. DAB staining was then performed using omni-map anti-rabbit HRP (Roche) according to the manufacturer's instructions (Ventana automat). Evaluation of both staining intensity and proportion of stained cells was performed. Two trained technicians independently and sequentially observed the same microscopic fields. Both proportion of stained cells and staining intensity were evaluated for each field. For each staining, 10 fields were randomly selected at the magnification that allowed the best visualization of the tissue. The scoring procedure was as follows: (i) the proportion of positively stained cells was estimated and assigned a score of 0 to 4 for each field (0 = 0-5%; 1 = 5-25%; 2 = 25-50%; 3 = 50-75%; and 4 = 75-100%); and (ii) the staining intensity was scored as 0, 1, 2, or 3, corresponding to the presence of negative, weak, intermediate, and strong brown staining, respectively. The final score for each field and each observer was the multiplication of the two values (0 = no staining in the tissue; 12 = tissue contains strongly stained cells). For each tissue type, 10 independent observation fields were scored in parallel for both staining intensity and proportion of labeled cells for each of the five slides in each slide set. Technicians simultaneously viewed a given field (virtual slide, on a computer screen) and scored independently, blinded to the results of the other observers. For each slide, the 10 scores from each technician were averaged to establish a final score for each observer. The final scores of the two observers were averaged to give the tissue score for a given slide. For human skin, only the results of the first set of reproducibility are presented.
[0123] Internalization assay Ten thousand SUM190PT or human differentiated keratinocytes (0.1 mM CaCl2 ) were seeded into 96-well plates and subsequently incubated with a range of doses (1.6 ng / mL to 1 μg / mL) of pHAB thiol-reactive dye-conjugated anti-nectin-4 mAb and isotype control for 24 h at 37 °C. After internalization and endolysosomal processing, the acidic environment causes the dye to fluoresce. Fluorescence intensity was monitored on a plate reader at an excitation wavelength of 532 nm and an emission wavelength of 560 nm.
[0124] In vitro cytotoxicity assay To analyze the in vitro cytotoxic activity of ADCs, cell viability was assessed using the AlamarBlue staining protocol recommended by the manufacturer (Biosource, CA, USA). The test incorporates a fluorescent redox indicator. Fluorescence intensity is proportional to the metabolic decline of cells. Experiments were performed by incubating 3000 cells / well (SUM190PT or differentiated NHEK) in triplicate with serial dilutions of ADCs on day 0 in 96-well plates. AlamarBlue was measured on day 5 by incubating 1 / 10 volume of alamarBlue solution at 37°C for 2 hours and reading at 595 nm (FLUOstar Optima, BMG Labtech).
[0125] Mouse experiments NOD / SCID (non-obese diabetic / severe combined immunodeficiency) / gc null mice (NSG) were obtained from Charles River Laboratory (Margate, UK). Six to seven week old females (n = 5 / group) were treated with 0.5 × 10 IgG1-embedded SUM190PT (0.5 × 10 6 10) cells were xeno-implanted orthotopically on both sides. Treatment with ADC was performed as mentioned in each experiment. Tumor size (n=10 / group) was monitored twice a week thereafter with calipers, and size was reported using the following formula (L×l×h×Pi / 6).
[0126] Hybridoma sequencing For hybridoma sequencing, RNA was first extracted from hybridoma cell pellets. cDNA was generated by reverse transcription, and the VH and VL domains were amplified by polymerase chain reaction using Prime STARMax DNA Polymerase (Takara). The PCR products were subsequently cloned into dedicated heavy and light chain expression vectors and then sequenced.
[0127] Generation, production, purification, and control of chimeric antibodies The light chain expression vector encodes the V kappa chain. Depending on the payload used, two different heavy chain expression vectors were used: one encoding an Fc fragment with the mutations D265C (ThiomAb) L234A and L235A, and the other encoding an Fc fragment with the mutations P331S, L234Q and L235F. Both Fc fragments are "Fc silent". The sequence of anti-nectin-4 Enfortumab (HA22) was also cloned into the same vector.
[0128] Light and heavy chain vectors were transfected into HEK293 seeded at a ratio of 1.2 / 1. After 6 days of production, culture supernatants were clarified and mAbs were purified using MabSelect PrismA resin (GE Healthcare) according to the manufacturer's instructions. 0.5 M glycine, 3 M NaCl, pH 8.9 was used as binding buffer and 0.1 M citric acid pH 3 was used for elution. Immediate neutralization was performed with 10% (V / V) 1 M Tris-HCl pH 9. Monoclonal chimeric antibodies were then dialyzed against PBS 1× pH 7.4 (Mini dialysis devices, 2 mL-10k, Thermo Scientific) and then filtered on a 0.22 μm filter (Milelex GV hydrophilic PVDF, Millipore). Concentrations were calculated based on the specific extinction coefficient (E 1% 280nmThe purity was determined using a Nanodrop 2000 Spectrophotometer (Thermo Scientific) taking into account the chromatographic purity of the chromatographic material. 4 The mass of the antibodies was determined by UPLC-SEC using an Acquity UPLC-HClass Bio (Waters) using a Protein-BEH 200A column equilibrated in 0.3 M NaCl pH 6.9. The mass of the antibodies was determined in a Xevo G2-S Q-Tof mass spectrometer (Waters) using a reversed-phase column (PLRP-S 4000A, Agilent technologies). All samples were analyzed after deglycosylation with PNGase F glycosidase (New England Biolabs) at 37°C according to the manufacturer's instructions. Fragmentation and / or aggregation of the final material was assessed by SDS-PAGE. Endotoxin load was determined using a chromogenic LAL-kinetic assay (Charles River Endosafe).
[0129] Antibody Conjugation The thiol-reactive dye pHAB (Promega) was conjugated to the cysteines of selected anti-Nectin-4 ThiomAb (D265C, L234A, L235A) antibodies using maleimide chemistry according to the manufacturer's instructions. Briefly, the antibodies were reduced at 2.5 mM for 1 h at room temperature under gentle agitation after dialysis against 0.1 M phosphate buffer pH 7.0. Subsequently, DTT was removed by washing / centrifugation twice on a Zeba spin desalting column (7 MWCO). 1.2 L of pHdye reagent (10 μg / mL DMSO) was added to 100 μg of antibody and incubated at room temperature for 1 h protected from light. After removal of excess dye on a Zeba desalting column, the dye-antibody ratio was calculated to confirm equivalent conjugation between the different antibodies.
[0130] The cysteine-reactive linker-exatecan compound maleimide-Gly-PSAR10-glucuronide-exatecan (MabLink) was conjugated to cysteine residues of selected anti-nectin-4 mAbs (P331S, L234Q and L235F). Briefly, mAbs in PBS 1×, 1 mM EDTA were reduced with 14 molar equivalents of TCEP for 2 h at 37° C., and then the buffer was changed to 100 mM KPO 4 The buffer was then exchanged into 1 mM EDTA pH 7.4 (Amicon ultra 30 kDa). 12 molar equivalents of cysteine reactive linker-exatecan compound were used to conjugate with the reactive cysteine for 35 minutes at room temperature. The buffer was then exchanged into 100 mM KPO 4 After pH exchange to 8.0, the maleimide was incubated at 37° C. in the absence of oxygen for 24 hours to allow autohydrolysis. A final buffer exchange was performed in 20 mM His pH 6.0 followed by filtration through a 0.22 μM filter. The drug-to-antibody ratio (DAR) by LC-MS analysis was between 7.77 and 7.82 toxins per conjugated mAb. Less than 8% of the material was aggregated as determined by SEC-HPLC. The invention as originally claimed in the present application is set forth below. [1] An antibody-drug conjugate comprising a monoclonal antibody or antigen-binding fragment thereof and a drug, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor. [2] The antibody-drug conjugate of [1], which comprises an antibody selected from a chimeric antibody, a multispecific antibody, particularly a bispecific antibody, a human antibody, a humanized antibody, or an antigen-binding fragment thereof. [3] The antibody-drug conjugate of [1] or [2] comprising an antibody selected from an antibody of class IgG, e.g., subclass IgG1, IgG2, IgG3 or IgG4, class IgM, class IgA, or an antigen-binding fragment thereof, or a single-chain antibody, or an antibody Fv fragment, optionally having a heavy chain constant domain with reduced effector function, e.g., reduced binding to Fc receptors. [4] An antibody-drug conjugate of any of [1] to [3], which contains an antibody, or an antigen-binding fragment thereof, that specifically binds with higher affinity to Nectin-4 expressed by tumors compared to Nectin-4 expressed by human differentiated keratinocytes. [5] (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 1 or 7, 88, 96 or 104, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 is an amino acid sequence according to SEQ ID NO: 2 or 8, 89, 97 or 105, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 is an amino acid sequence according to SEQ ID NO: 3, or 9, 90, 98, or 106, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 4 or 10, 92, 100 or 108, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 comprises an amino acid sequence according to SEQ ID NO: 5 or 11, 93, 101 or 109, or an amino acid sequence comprising a substitution or insertion, in particular a conservative substitution and / or a histidine insertion, of at least one amino acid, e.g. one or two amino acids, (iii) a VL region, the CDR-L3 of which comprises an amino acid sequence according to SEQ ID NO: 6 or 12, 94, 102 or 110, or an amino acid sequence containing a substitution or insertion, in particular a conservative substitution and / or a histidine insertion, of at least one amino acid, e.g., one or two amino acids. The antibody-drug conjugate of any one of [1] to [4], comprising an antibody or an antigen-binding fragment thereof. [6] (a)(i) a VH region comprising CDR-H1 of SEQ ID NO: 1, CDR-H2 of SEQ ID NO: 2, and CDR-H3 of SEQ ID NO: 3, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6; or (b)(i) a VH region comprising CDR-H1 of SEQ ID NO: 7, CDR-H2 of SEQ ID NO: 8, and CDR-H3 of SEQ ID NO: 9, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 10, CDR-L2 of SEQ ID NO: 11, and CDR-L3 of SEQ ID NO: 12; or (c)(i) a VH region comprising CDR-H1 of SEQ ID NO: 88, CDR-H2 of SEQ ID NO: 89, and CDR-H3 of SEQ ID NO: 90, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 92, CDR-L2 of SEQ ID NO: 93, and CDR-L3 of SEQ ID NO: 94; or (d)(i) a VH region comprising CDR-H1 of SEQ ID NO: 96, CDR-H2 of SEQ ID NO: 97, and CDR-H3 of SEQ ID NO: 98, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 100, CDR-L2 of SEQ ID NO: 101, and CDR-L3 of SEQ ID NO: 102; or (e)(i) a VH region comprising CDR-H1 of SEQ ID NO: 104, CDR-H2 of SEQ ID NO: 105, and CDR-H3 of SEQ ID NO: 106, and optionally (ii) a VL region comprising CDR-L1 of SEQ ID NO: 108, CDR-L2 of SEQ ID NO: 109, and CDR-L3 of SEQ ID NO: 110 The antibody-drug conjugate of any one of [1] to [5], comprising an antibody or an antigen-binding fragment thereof. [7] (a) a VH region comprising an amino acid sequence of SEQ ID NO: 13, 91, 99, or 107, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and optionally (b) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, 95, 103 or 111, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. The antibody-drug conjugate of any one of [1] to [6], comprising an antibody or an antigen-binding fragment thereof. [8] (a)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 13, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereto; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 14, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (b)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 91, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 95, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (c)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 99, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 103, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto; or (d)(i) a VH region comprising an amino acid sequence according to SEQ ID NO: 107, or an amino acid sequence having at least 85%, at least 90%, at least 95%, or at least 99% identity thereof; and optionally (ii) a VL region, in particular a VL region comprising an amino acid sequence according to SEQ ID NO: 111, or an amino acid sequence having at least 85%, at least 90%, at least 95% or at least 99% identity thereto. The antibody-drug conjugate of any of [1] to [7], comprising an antibody or an antigen-binding fragment thereof. [9] (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 is an amino acid sequence according to SEQ ID NO: 21, 35, 49 or 63, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 22, 36, 50 or 64, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 23, 37, 51 or 65, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 24, 38, 52 or 66, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 is an amino acid sequence according to SEQ ID NO: 25, 39, 53 or 67, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 is an amino acid sequence according to SEQ ID NO: 26, 40, 54 or 68, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, The antibody-drug conjugate of any of [1] to [9], comprising an antibody or an antigen-binding fragment derived therefrom.
[10] (a) a variable heavy chain (VH) region comprising complementarity determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, (i) the CDR-H1 has an amino acid sequence according to SEQ ID NO: 72 or 80, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-H2 has an amino acid sequence according to SEQ ID NO: 73 or 81, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-H3 has an amino acid sequence according to SEQ ID NO: 74 or 82, or a substitution or insertion, in particular a conservative substitution and / or histidine insertion of at least one amino acid, e.g., one or two amino acids, in a VH region; and optionally (b) a variable light chain (VL) region, in particular a VL region comprising complementarity determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, (i) the CDR-L1 is an amino acid sequence according to SEQ ID NO: 75 or 84, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (ii) the CDR-L2 has an amino acid sequence according to SEQ ID NO: 76 or 85, or an amino acid sequence which comprises a substitution or insertion, in particular a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, (iii) the CDR-L3 has an amino acid sequence according to SEQ ID NO: 77 or 86, or a substitution or insertion, in particular an amino acid sequence containing a conservative substitution and / or a histidine insertion of at least one amino acid, e.g., one or two amino acids, The antibody-drug conjugate of any one of [1] to [3], which comprises an antibody or an antigen-binding fragment derived therefrom.
[11] The antibody-drug conjugate of any of [1] to
[10] , wherein the topoisomerase I inhibitor is camptothecin or an analogue thereof, and the topoisomerase I inhibitor is, in particular, exatecan or deruxtecan.
[12] Any of the antibody-drug conjugates of [1] to
[11] , having a drug-antibody / antibody fragment molar ratio (DAR) of about 2:1 to about 16:1, specifically about 4:1 to about 10:1, and more specifically about 6:1 to about 8:1.
[13] The antibody-drug conjugate of any of [1] to
[12] , wherein the drug is conjugated to a reactive amino acid residue on the antibody, for example, an amino acid residue having a side chain containing an amino group, a hydroxyl group, or a thiol group, or a reactive group in an antibody glycan structure, and the drug is particularly conjugated to a reactive thiol group in the side chain of a cysteine residue on the antibody or antigen-binding fragment thereof.
[14] The antibody-drug conjugate of any of [1] to
[13] , wherein the drug is conjugated to the antibody or antigen-binding fragment thereof via a linker, and in particular the linker is a cleavable linker, and / or the linker is in particular a hydrophilic polysarcosine linker, a hydrophilic linker comprising at least one ethylene glycol unit, a linker comprising a highly polar spacer, or an oligopeptide linker.
[15] The antibody-drug conjugate of
[14] , wherein the linker is a hydrophilic polysarcosine linker and at least one ethylene glycol unit, wherein the linker is subject to cleavage by glycosidases, in particular by glucuronidase.
[16] The antibody-drug conjugate of
[14] or
[15] , wherein the linker is a hydrophilic polysarcosine linker comprising, for example, about 8-12 sarcosine units and at least one ethylene glycol unit, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more ethylene glycol units, wherein the linker is subject to cleavage by glycosidases, in particular glucuronidases.
[17] An antibody-drug conjugate of any of
[14] to
[16] , wherein the linker is a hydrophilic polysarcosine linker containing 10 sarcosine units and 2 ethylene glycol units.
[18] An antibody-drug conjugate of any of
[14] to
[17] , wherein the linker is cleaved by glucuronidase.
[19] Any of the antibody-drug conjugates of
[14] to
[18] , wherein the linker is attached to a cysteine residue on the antibody or antigen-binding fragment thereof via a thiol-reactive group, in particular a maleimide group.
[20] A pharmaceutical composition comprising an active agent that is an antibody-drug conjugate comprising a monoclonal antibody or antigen-binding fragment thereof, wherein the monoclonal antibody or antigen-binding fragment thereof binds to Nectin-4, and the drug is a topoisomerase I inhibitor, and a pharma- ceutical composition comprising a pharma-ceutical acceptable carrier and / or excipient.
[21] Use of an antibody-drug conjugate of any of [1] to
[19] or a pharmaceutical composition of
[19] in medicine, particularly in human medicine.
[22] Use of an antibody-drug conjugate of any of [1] to
[19] or the pharmaceutical composition of
[19] in a method for preventing and / or treating a Nectin-4-associated disorder, in particular for preventing and / or treating a Nectin-4-positive cancer, in particular for preventing and / or treating a cancer selected from bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.
Claims
1. An antibody-drug conjugate comprising a monoclonal antibody or an antigen-binding fragment thereof and a drug, wherein the monoclonal antibody or the antigen-binding fragment thereof binds to Nectin-4; The monoclonal antibody is (a)(i) a variable heavy (VH) region comprising complementarity determining regions (CDRs), which are CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:1, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:2, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:3; and (ii) a variable light (VL) region comprising complementarity determining regions (CDRs), which are CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO:4, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO:5, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO:6; Contains or (b)(i) a variable heavy (VH) region comprising complementarity determining regions (CDRs), which are CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO:7, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO:8, and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO:9; and (ii) a variable light (VL) region comprising complementarity determining regions (CDRs), CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 10, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 11, and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 12; Including, An antibody-drug conjugate, wherein the drug is a topoisomerase I inhibitor.
2. The antibody-drug conjugate of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is selected from a chimeric antibody, a multispecific antibody, a humanized antibody, or an antigen-binding fragment thereof.
3. 3. The antibody-drug conjugate of claim 1 or 2, comprising an antibody selected from antibodies of class IgG, class IgM, class IgA, or an antigen-binding fragment thereof, or a single chain antibody, or an antibody Fv fragment.
4. (i) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence having at least 90%, at least 95%, or at least 99% identity thereto; and (ii) a VL region comprising an amino acid sequence as set forth in SEQ ID NO: 14, or an amino acid sequence having at least 90%, at least 95%, or at least 99% identity thereto; The antibody-drug conjugate of any one of claims 1 to 3, comprising an antibody or an antigen-binding fragment thereof comprising:
5. The antibody-drug conjugate of any one of claims 1 to 4, wherein the topoisomerase I inhibitor is camptothecin.
6. An antibody-drug conjugate described in any one of claims 1 to 4, wherein the topoisomerase I inhibitor is indenoisoquinoline or indolocarbazole.
7. A pharmaceutical composition comprising an active agent which is the antibody-drug conjugate of any one of claims 1 to 5, and a pharma- ceutically acceptable carrier and / or excipient.
8. Use of an antibody-drug conjugate according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 7 in medicine.
9. The antibody-drug conjugate of any one of claims 1 to 5 for use in the treatment of a Nectin-4 associated disorder.
10. The pharmaceutical composition of claim 7 for use in the treatment of a Nectin-4 associated disorder.
11. The antibody-drug conjugate of any one of claims 1 to 5, wherein the antibody is a chimeric antibody or an antigen-binding fragment thereof.
12. The antibody-drug conjugate of any one of claims 1 to 5, wherein the antibody is a humanized antibody or an antigen-binding fragment thereof.
13. The antibody-drug conjugate according to any one of claims 1 to 5, wherein the antibody is an antibody of subclass IgG1 or an antigen-binding fragment thereof.
14. The antibody-drug conjugate according to any one of claims 1 to 5, wherein the antibody is an antibody of subclass IgG2 or an antigen-binding fragment thereof.
15. The antibody-drug conjugate according to any one of claims 1 to 5, wherein the antibody is an antibody of subclass IgG3 or an antigen-binding fragment thereof.
16. The antibody-drug conjugate of any one of claims 1 to 5, wherein the antibody is an antibody of subclass IgG4 or an antigen-binding fragment thereof.
17. The antibody-drug conjugate of any one of claims 1 to 5, wherein the antibody has a heavy chain constant domain with a reduced effector function that is reduced binding to Fc receptors.
18. The antibody-drug conjugate of any one of claims 1 to 5, wherein the topoisomerase I inhibitor is exatecan.
19. The antibody-drug conjugate of any one of claims 1 to 5, wherein the topoisomerase I inhibitor is deruxtecan.
20. The antibody-drug conjugate of any one of claims 1 to 5 for use in the treatment of Nectin-4 positive cancer.
21. The pharmaceutical composition according to claim 7 for use in treating Nectin-4 positive cancer.
22. 6. The antibody-drug conjugate of any one of claims 1 to 5 for use in the treatment of a cancer selected from bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.
23. 8. The pharmaceutical composition of claim 7 for use in the treatment of a cancer selected from bladder cancer, urothelial cancer, endometrial cancer, cervical cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, pancreatic cancer, lung cancer, ovarian cancer, head and neck cancer and / or esophageal cancer.
Citation Information
Patent Citations
Antibodies with specificity for Nectin-4 and uses thereof
JP2018531913A
Antibodies specific to NECTIN-4 and uses thereof
JP2020510432A
